Well, the FDA has ruled on the AZN / BMY drug dapagliflozin for the treatment of diabetes. It comes as no surprise that they feel the benefits do not outweigh the risks. As was pointed out here in July 2011, the unknowns about safety that were also raised by the Advisory Committee, make for a difficult approval. The only good thing that can be said for this new class of drugs is that the FDA has set the bar for approval. Those that follow AZN and BMY with NDA submissions are well advised to clear the bar.
Posts tagged ‘azn’